3M Company · MMM · FY2024 Q4 · Calendar Q1 2025
3M Maintains Outlook While Focusing on Productivity and Innovation
The supplied analysis supports a constructive but qualified view: management paired a confident operating plan with maintained guidance, while execution on productivity, service levels and product innovation remains necessary to sustain the trajectory.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about MMM FY2024 Q4
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The latest analysis shifts emphasis toward the execution of the 2025 operating plan: improving service and inventory metrics, advancing new products and managing the portfolio, while maintaining the outlook.
Guidance delta
Management maintained its outlook, with the supplied analysis pointing to continued organic growth, earnings and margin improvement priorities.
Key takeaways
- Management described fourth-quarter and full-year performance as ahead of guidance.
- Operational priorities center on productivity, higher OTIF, lower inventory days and operating-efficiency gains.
- New product introductions and commercial execution remain important supports for the growth outlook.
Management priorities
- Improve OTIF and reduce inventory days.
- Expand new-product introductions and commercial execution.
- Continue portfolio assessment and planned capital deployment.
Follow MMM with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 19, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Overweight | Overweight | Maintain | Oct 9, 2026 |
| Bernstein | Market Perform | Underperform | Upgrade | Sep 25, 2026 |
| Mizuho | Neutral | Neutral | Maintain | Jul 23, 2026 |
| UBS | Buy | Buy | Maintain | Jul 22, 2026 |
| RBC Capital | Underperform | Underperform | Maintain | Jul 22, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 22, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 22, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 1, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jan 21, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Jan 21, 2026 |
| B of A Securities | Buy | Buy | Maintain | Mar 6, 2025 |
| Melius Research | Buy | Hold | Upgrade | Oct 22, 2024 |
| Argus Research | Buy | Hold | Upgrade | Jul 30, 2024 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jun 13, 2024 |
| Vertical Research | Buy | Hold | Upgrade | May 16, 2024 |
| HSBC | Buy | Hold | Upgrade | May 10, 2024 |
| DA Davidson | Buy | Buy | Maintain | Jul 11, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Mar 29, 2023 |
| Goldman Sachs | Neutral | Neutral | Maintain | Oct 11, 2022 |
| Jefferies | Hold | Hold | Maintain | Jun 16, 2022 |
| CFRA | Hold | Sell | Upgrade | Mar 8, 2022 |
| Langenberg & Company | Buy | Hold | Upgrade | Oct 10, 2021 |
| Gordon Haskett | Hold | Underperform | Upgrade | Oct 7, 2020 |
| Bank of America | Neutral | Neutral | Maintain | Jun 27, 2019 |
| Argus | Hold | Buy | Downgrade | Apr 26, 2019 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 25, 2018 |
| Stifel | Hold | Hold | Maintain | Apr 25, 2018 |
| Hilliard Lyons | Buy | Neutral | Upgrade | Jan 24, 2018 |
| Argus Capital | Buy | Hold | Upgrade | Jul 8, 2014 |
| William Blair | Market Perform | Market Perform | Maintain | Feb 25, 2014 |
| Ladenburg Thalmann | Hold | Hold | Maintain | Dec 26, 2013 |
| Nomura | Buy | Neutral | Upgrade | Dec 11, 2013 |
| FBR Capital | Outperform | Outperform | Maintain | Oct 25, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $163.23. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Bernstein | Analyst unavailable | $171 | $167.52 | +4.8% | Sep 25, 2026 |
| Wells Fargo | Analyst unavailable | $195 | $167.52 | +19.5% | Sep 24, 2026 |
| Mizuho Securities | Analyst unavailable | $180 | $170.08 | +10.3% | Jul 23, 2026 |
| Deutsche Bank | Nicole Deblase | $192 | $173.97 | +17.6% | Jul 22, 2026 |
| UBS | Analyst unavailable | $218 | $170.76 | +33.6% | Jul 22, 2026 |
| Bernstein | Varun Govindaraj | $145 | $170.76 | -11.2% | Jul 22, 2026 |
| Goldman Sachs | Analyst unavailable | $190 | $158.32 | +16.4% | Jun 15, 2026 |
| Deutsche Bank | Analyst unavailable | $181 | $158.06 | +10.9% | Jan 21, 2026 |
| Mizuho Securities | Brett Linzey | $160 | $157.45 | -2.0% | Jan 21, 2026 |
| RBC Capital | Deane Dray | $136 | $156.09 | -16.7% | Jan 21, 2026 |
| RBC Capital | Deane Dray | $131 | $172.79 | -19.7% | Jan 15, 2026 |
| Deutsche Bank | Nicole Deblase | $178 | $167.48 | +9.0% | Dec 8, 2025 |
| Barclays | Analyst unavailable | $190 | $173.09 | +16.4% | Dec 4, 2025 |
| UBS | Amit Mehrotra | $190 | $166.64 | +16.4% | Oct 22, 2025 |
| Barclays | Julian Mitchell | $180 | $166.64 | +10.3% | Oct 22, 2025 |
| Morgan Stanley | Analyst unavailable | $160 | $166.64 | -2.0% | Oct 21, 2025 |
| Barclays | Julian Mitchell | $170 | $159.04 | +4.1% | Jul 18, 2025 |
| UBS | Markus Mittermaier | $184 | $130.35 | +12.7% | Nov 12, 2024 |
| Bank of America Securities | Andrew Obin | $160 | $129.04 | -2.0% | Oct 23, 2024 |
| RBC Capital | Deane Dray | $100 | $131.73 | -38.7% | Oct 23, 2024 |
| CFRA | Jonathan Sakraida | $165 | $131.73 | +1.1% | Oct 22, 2024 |
| Citigroup | Andrew Kaplowitz | $133 | $134.84 | -18.5% | Oct 22, 2024 |
| Mizuho Securities | Brett Linzey | $146 | $135.73 | -10.6% | Oct 16, 2024 |
| Barclays | Julian Mitchell | $160 | $137.06 | -2.0% | Oct 2, 2024 |
| Jefferies | Laurence Alexander | $146 | $135.64 | -10.6% | Sep 24, 2024 |
| Morgan Stanley | Christopher Snyder | $125 | $131.4 | -23.4% | Sep 6, 2024 |
| Deutsche Bank | Nicole Deblase | $150 | $126.94 | -8.1% | Jul 31, 2024 |
| Argus Research | John Eade | $145 | $126.75 | -11.2% | Jul 30, 2024 |
| RBC Capital | Deane Dray | $95 | $125.3 | -41.8% | Jul 29, 2024 |
| Wells Fargo | Joe O'Dea | $110 | $103.39 | -32.6% | Jul 26, 2024 |
| RBC Capital | Deane Dray | $78 | $94.02 | -52.2% | Apr 2, 2024 |
| CFRA | Jonathan Sakraida | $100 | $94.02 | -38.7% | Apr 1, 2024 |
| RBC Capital | Deane Dray | $84 | $108.11 | -48.5% | Mar 20, 2024 |
| Barclays | Julian Mitchell | $126 | $105.32 | -22.8% | Mar 19, 2024 |
| Citigroup | Andrew Kaplowitz | $104 | $92.42 | -36.3% | Feb 15, 2024 |
| Morgan Stanley | Joshua Pokrzywinski | $113 | $93 | -30.8% | Sep 28, 2023 |
| J.P. Morgan | Stephen Tusa | $105 | $97.03 | -35.7% | May 25, 2023 |
| Morgan Stanley | Joshua Pokrzywinski | $102 | $100.96 | -37.5% | May 10, 2023 |
| Mizuho Securities | Brett Linzey | $130 | $120.66 | -20.4% | Dec 27, 2022 |
| Wells Fargo | Joseph O’Dea | $137 | $128.31 | -16.1% | Jul 15, 2022 |
| Deutsche Bank | Nicole DeBlase | $146 | $128.37 | -10.6% | Jul 14, 2022 |
| Barclays | Julian Mitchell | $143 | $126.59 | -12.4% | Jul 14, 2022 |
| Jefferies | Laurence Alexander | $145 | $129.84 | -11.2% | Jun 20, 2022 |
| Barclays | Analyst unavailable | $146 | $145.41 | -10.6% | Apr 27, 2022 |
| Credit Suisse | Analyst unavailable | $161 | $144.88 | -1.4% | Apr 27, 2022 |
| Morgan Stanley | Analyst unavailable | $138 | $144.87 | -15.5% | Apr 27, 2022 |
| RBC Capital | Analyst unavailable | $138 | $144.22 | -15.5% | Apr 27, 2022 |
| Deutsche Bank | Nicole DeBlase | $167 | $146.18 | +2.3% | Apr 19, 2022 |
| Barclays | Julian Mitchell | $155 | $148.9 | -5.0% | Apr 5, 2022 |
| Wells Fargo | Joseph O’Dea | $173 | $147.62 | +6.0% | Feb 21, 2022 |
| Deutsche Bank | Nicole Deblase | $182 | $155.83 | +11.5% | Feb 15, 2022 |
| Argus Research | John Eade | $190 | $167.68 | +16.4% | Jan 26, 2022 |
| Credit Suisse | John Walsh | $195 | $169.3 | +19.5% | Jan 26, 2022 |
| Wolfe Research | Nigel Coe | $190 | $167.68 | +16.4% | Jan 26, 2022 |
| Bernstein | Brendan Luecke | $175 | $175.71 | +7.2% | Jan 10, 2022 |
| Bank of America Securities | Andrew Obin | $185 | $178.3 | +13.3% | Sep 17, 2021 |
Track every rating change on MMM the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publication3M Company operates as a global technology conglomerate with diverse interests. Its extensive operations are strategically divided into four primary business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial division supplies a broad array of products, including specialized abrasives and finishing tools for metalworking, automotive body repair kits, fastening systems for personal hygiene items, various masking and packaging materials, electrical components for construction, maintenance, and power distribution, strong structural adhesives and tapes, comprehensive personal protective equipment for respiratory, auditory, visual, and fall protection, and mineral granules for roofing shingles.…
Historical context
All MMM earningsIndustrials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| JBHT J.B. Hunt Transport Services, Inc. | FY2026 Q3 · Calendar Q4 2026 | +0.6% | -2.0% | J.B. Hunt: Strong demand, but margin repair remains central |
| FAST Fastenal Company | FY2026 Q3 · Calendar Q4 2026 | +3.3% | +1.1% | Fastenal Q3: Share Gains and Digital Adoption Lift Growth |
Latest beats and misses
Who reports nextBeat on EPS
Missed on EPS
Get the MMM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-09T15:58:31.122891+00:00
- Polygon adjusted daily market bars · 2026-10-19T18:30:57.849099+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-19T18:30:57.846330+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-19. For educational purposes only; not investment advice.